GlassScriptPhysician profile
Ashley Probus
NPI 1578010419
$1,793.10
in general payments reported to CMS, 2019-2025
34 companies · $892 in 2025
The $892 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $41.44 · 2023: $289 · 2024: $571 · 2025: $892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,752.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,751.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $244.47 | 2022-2025 | Jakafi, Monjuvi, Niktimvo |
| Abbvie INC. | $146.22 | 2024-2025 | |
| Celgene Corporation | $144.59 | 2024-2025 | Reblozyl |
| Genentech USA, INC. | $110.01 | 2023-2025 | Venclexta, Polivy |
| Astellas Pharma US INC | $98.91 | 2024-2025 | Cresemba, Xospata |
| Janssen Biotech, INC. | $83.32 | 2023-2025 | Carvykti, Talvey, Tecvayli |
| Adc Therapeutics America, INC. | $71.52 | 2023-2025 | |
| Blueprint Medicines Corporation | $67.10 | 2024-2025 | Ayvakit |
| Beigene USA, INC. | $66.85 | 2023-2025 | Brukinsa |
| Sanofi-Aventis U.S. LLC | $63.67 | 2023-2025 | |
| Genmab U.S., INC. | $58.43 | 2023-2024 | Epkinly |
| Novartis Pharmaceuticals Corporation | $56.76 | 2025 | |
| Rigel Pharmaceuticals, INC. | $43.96 | 2024-2025 | Rezlidhia, Gavreto, Tavalisse |
| Takeda Pharmaceuticals U.S.A., INC. | $42.02 | 2025 | Iclusig |
| Glaxosmithkline, LLC. | $41.63 | 2024-2025 | Ojjaara |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $37.92 | 2024 | Jaypirca, Verzenio, Retevmo |
| E.R. Squibb & Sons, L.L.C. | $34.99 | 2025 | Breyanzi |
| Adaptive Biotechnologies Corporation | $34.48 | 2023 | Clonoseq |
| Pfizer INC. | $33.42 | 2023-2024 | |
| Sobi, INC | $30.17 | 2025 | |
| Daiichi Sankyo INC. | $29.27 | 2024 | Vanflyta |
| Bayer Healthcare Pharmaceuticals INC. | $28.81 | 2022-2023 | |
| Legend Biotech USA INC. | $24.57 | 2025 | Carvykti |
| Alexion Pharmaceuticals, INC. | $23.83 | 2025 | Ultomiris |
| Genzyme Corporation | $20.79 | 2025 | |
| Cumberland Pharmaceuticals, INC. | $20.56 | 2024 | Sancuso |
| Pharmacosmos Therapeutics INC. | $18.26 | 2023 | Monoferric |
| Sumitomo Pharma America, INC. | $17.74 | 2024 | Orgovyx |
| Merck Sharp & Dohme LLC | $17.59 | 2024 | Reblozyl |
| Regeneron Healthcare Solutions, INC. | $17.42 | 2025 | Lynozyfic |
| Gilead Sciences, INC. | $17.28 | 2024 | |
| Syndax Pharmaceuticals, INC. | $16.68 | 2025 | |
| Karyopharm Therapeutics INC. | $15.22 | 2023 | Xpovio |
| Pharmacyclics LLC, An Abbvie Company | $14.64 | 2023 | Imbruvica |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Probus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.